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Purpose: The cloned enzyme donor immunoassay (CEDIA) for buprenorphine is applied for 
both urine drugs-of-abuse screening and compliance monitoring. Sensitivity, specificity, and 
optimal cutoff of this assay have differed between studies. This may indicate that cross-reactivity 
has to be taken into account during assay evaluation. We therefore investigated the performance 
of the CEDIA buprenorphine assay for use in our patient population and explored the impact 
of cross-reactivity on assay accuracy.
Methods: The CEDIA buprenorphine assay and high-performance liquid chromatography–
tandem mass spectrometry were employed to analyze drugs-of-abuse in urine samples from a 
healthy drug-naïve male volunteer after intake of two tablets of a prescription drug containing 
400 mg paracetamol +30 mg codeine phosphate, and in urine samples (n=2,272) from drug-
addicted patients. Receiver operating characteristic analyses were performed to express the 
diagnostic accuracy of the CEDIA buprenorphine assay.
Results: CEDIA buprenorphine was positive in one urine sample from the drug-naïve person 
after intake of the prescription drug. Twenty-five (1.1%) of the patient urine samples were positive 
for buprenorphine by CEDIA, but negative by high-performance liquid chromatography–tandem 
mass spectrometry. Codeine, morphine, and their respective metabolites were prevalent in 
samples that were false positive for buprenorphine. The specificity of the CEDIA buprenorphine 
assay increased to 99.7% when the cutoff was increased from 5 ng/mL to 10 ng/mL.
Conclusion: Intake of a therapeutic dose of codeine can yield a false-positive CEDIA 
buprenorphine result. Additive effects from metabolites of codeine contribute to cross-reactivity 
in concentrations much lower than listed in the manufacturer’s cross-reactivity guide. Raising 
the cutoff from 5 ng/mL to 10 ng/mL increased the diagnostic accuracy. Clinicians should be 
informed about the risk of false-positive results with the CEDIA buprenorphine assay.
Keywords: buprenorphine, codeine, cross-reactivity, urine drugs-of-abuse screening, 
immunoassay
Introduction
Buprenorphine is a partial agonist/antagonist on the opioid receptors and may be 
prescribed both as an analgetic and in medication-assisted rehabilitation (MAR) of 
opioid-dependent patients.1 Buprenorphine was reported as the third most prevalent 
misused opioid, next to heroin and methadone.2 Although it seems to be more 
frequently misused in Europe and Asia than in the US,3 a 384% increase of misuse 
has been reported between 2006 and 2011 in the US.4 Thus, urine drug screening of 
buprenorphine is used to monitor compliance in MAR and side abuse.5
Chromatographic methods with mass spectrometry have high diagnostic accuracy 
but are time consuming and resource demanding.6 Immunochemical methods may be 





preferential because they do not require the same degree of 
training and competence among laboratory staff and because 
they have a fast response time.7
Cross-reactivity leading to false-positive results is a 
known problem when using immunochemical methods.8 
The producer of the cloned enzyme donor immunoas-
says (CEDIAs) has published a cross-reactivity guide9 
that presents an overview over compounds that gave 
false-positive results in samples spiked with the poten-
tial cross-reactant over a range of clinically achievable 
concentrations. However, cross-reactivity with metabolites 
was not fully evaluated. Furthermore, in a clinical setting, 
several structurally related substances may be present 
simultaneously in urine samples from addicted patients, 
which may increase the potential of unintended analytical 
interference. The CEDIA buprenorphine assay has been 
associated with cross-reactivity with various substances, 
especially structurally related opioids such as morphine 
and codeine.5,10,11 Both sensitivity and specificity have dif-
fered between studies of this assay, even though a cutoff of 
5 ng/mL was applied in all.5,10,12 Typically in these cases, the 
signal in the false-positive samples has been only slightly 
above the manufacturer’s recommended 5 ng/mL cutoff 
concentration. Hence, the choice of an appropriate cutoff is 
of particular relevance for the performance of the CEDIA 
buprenorphine assay in a given population.
The urine drugs-of-abuse screening panel in our labora-
tory is used in a therapeutic setting and covers commonly 
abused drugs such as amphetamines, benzodiazepines, 
and opioids, including methadone and buprenorphine, 
which are of particular relevance to patients included in 
MAR. Positive buprenorphine screening results, indi-
cating buprenorphine abuse in patients not treated with 
buprenorphine, could trigger a tighter therapeutic control 
or imply more serious consequences, such as exclusion 
from institutional therapy or loss of social benefits. This 
underlines that analytical specificity is of greater thera-
peutic significance than sensitivity. We regularly receive 
inquiries from clinicians questioning positive CEDIA 
buprenorphine results.
We therefore examined cross-reactivity by comparing 
the results obtained by CEDIA with those acquired by high-
performance liquid chromatography–tandem mass spectrom-
etry (HPLC-MS/MS). We first examined whether intake of a 
therapeutically recommended dose of a codeine preparation 
could yield false-positive CEDIA buprenorphine results. We 
then investigated which cutoff concentration would render 




The study material included anonymous, retrospective data 
used for quality control purposes in our department. The case 
study included only one of the authors (JS), and involved 
no patients. Thus, the study did not need formal approval or 
registration as a clinical trial according to the guidelines of the 
Regional Committee for Medical and Health Research Ethics 
and the Norwegian Data Protection Officer for Research at 
the Haukeland University Hospital. Furthermore, no patient 
consent was necessary.
In the case study, one healthy drug-naïve male  volunteer 
(JS) was given two tablets of Paralgin Forte® (codeine 
phosphate 30 mg/paracetamol 400 mg). Sixteen urine samples, 
including one sample collected before  administration of the 
drug, were collected from the volunteer during the following 
55 hours. The samples were analyzed for buprenorphine with 
the CEDIA assay and for opioids and metabolites, including 
codeine with HPLC-MS/MS.
In the performance study, 2,272 urine samples that had 
been sent to the laboratory at the Haukeland University 
Hospital for drugs-of-abuse screening during a 4-week period 
were analyzed with both CEDIA and HPLC-MS/MS. Samples 
were taken from patients treated with either buprenorphine 
or methadone in specialized MAR clinics and from patients 
in general practices, psychiatric wards, outpatient clinics, 
emergency units, and other treatment institutions for drug 
addiction. Based on the information given on the requisition 
forms, 43% (n=996) of the patients were MAR patients. Due 
to the possibility of cross-reactivity in the immunochemical 
methods, all samples were analyzed for the complete drugs-
of-abuse panel available at our laboratory, regardless of which 
analyses that had been required.
Analytical methods
All urine samples were tested for specimen validity tests 
including creatinine and pH before parallel analysis of 
CEDIA and HPLC-MS/MS. Urine samples with creatinine 
concentrations .2.3 mg/dL and with pH between 4.5 and 
8.0 were considered valid.
The CEDIA buprenorphine assay was performed on 
AU-680 (Beckman Coulter Biomedical Limited, Brea, 
CA, USA), and the reagents were supplied by Thermo-
Fischer  Scientif ic (Waltham, MA, USA). The assay 
was performed semiquantitatively using calibrators for 
buprenorphine containing 0 ng/mL, 5 ng/mL, 20 ng/mL, 
and 50 ng/mL. According to the manufacturer’s recom-
mendation, we employed a cutoff concentration of 5 ng/mL 
for buprenorphine. The total  analytical imprecision was 
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,9% at the manufacturer’s recommended cutoff concen-
tration. Total analytical imprecision was calculated using 
one measurement per day for 30 days. Imprecision mea-
surement for CEDIA buprenorphine was performed with 
CEDIA buprenorphine, low and high controls, and with 
drugs of abuse (DOA) total level 4. All control materials 
were supplied by Thermo-Fischer Scientific. The CEDIA 
buprenorphine assay is reported to have cross-reactivity 
of 100% for buprenorphine and for buprenorphine-3-
glucuronide, but no cross-reactivity for norbuprenorphine 
or norbuprenorphine-3-glucuronide.9 Performance of the 
CEDIA buprenorphine assay was investigated by comparison 
with HPLC-MS/MS. The samples were prepared using a 
 Hamilton AT2plus (Hamilton Robotics GmbH, Martinsried, 
Germany) and analyzed on an API 2000 (AB Sciex, 
Stockholm, Sweden) with a TurboIonSpray-ionization source 
and an 1100-series HPLC-system (Agilent Technologies, 
Waldbronn, Germany). Separation was achieved using a 
Supelco Ascentis Phenyl, 2.1 mm ×50 mm, 3 µm analytical 
column maintained at 30°C (Sigma-Aldrich, St Louis, MO, 
USA) using gradient elution with 0.1% formic acid in water 
and acetonitrile as mobile phases. The sample preparation 
consisted of a twofold dilution with eleven deuterated inter-
nal standards and 0.1% formic acid in water. No preanalyti-
cal hydrolysis was performed. Only one multiple reaction 
monitoring-transition per analyte was monitored. However, 
both the parent drug and at least one metabolite were moni-
tored. This was done because some analytes showed limited 
fragmentation and the presence of metabolites confirms 
intake of a specific drug. The limit of detection for buprenor-
phine, buprenorphine-glucuronide, norbuprenorphine, and 
norbuprenorphine-glucuronide was 0.9 ng/mL, 1.8 ng/mL, 
1.9 ng/mL, and 2.4 ng/mL, respectively. Total analytical 
imprecision at 10 ng/mL was 14.7%, 18.6%, 32.9%, and 
29.8% for  buprenorphine, buprenorphine-glucuronide, 
norbuprenorphine, and norbuprenorphine-glucuronide, 
respectively. The method also included analyzes of codeine 
and morphine and its metabolites, other opioids, and other 
drugs-of-abuse. Analytical performance data for these ana-
lytes as measured by HPLC-MS/MS is given in Table S1.
In order to increase specificity, total buprenorphine, 
norbuprenorphine, and benzodiazepines were additionally 
analyzed with a different HPLC-MS/MS method, which 
involved enzymatic hydrolysis. The sample preparation con-
sisted of a twofold dilution with β-glucuronidase (5,000 units/
mL urine) from Escherichia coli (G7396, Sigma-Aldrich), 
eight deuterated internal standards and BIS-TRIS–propane 
buffer (pH 6.8). The samples were then incubated at 37°C for 
2 hours. The hydrolysis was stopped by ultrafiltration using 
a 10 kD membrane filter plate (MultiScreen Ultracel-10; 
Merck Millipore, Billerica, MA, USA). Two multiple reac-
tion monitoring-transitions per analyte were monitored with 
set criteria for relative intensity, which gives identification 
points considered to provide reliable analyte identification.13 
The acceptance criteria for quantifier and qualifier ions 
were a signal-to-noise ratio of $10 and $3, respectively. 
The efficiency of the hydrolysis step for buprenorphine-
glucuronide was evaluated in each sample by comparing the 
results of the two HPLC-MS/MS methods.
Validation included linearity of the method, limits of 
detection and quantification, imprecision and accuracy, 
matrix effect, carryover, hydrolysis efficiency, chromato-
graphic interferences, and stability of processed samples. 
Quality control of the HPLC-MS/MS methods was performed 
using home-made spiked urine control material. Duplicate 
quality controls with two concentration levels were included 
in every series. The methods are part of the Labquality’s EQA 
(external quality assessment) program for drug abuse screen-
ing in urine and LGC Standards drugs of abuse in urine PT 
(proficiency testing) scheme.
Cross-reactivity of codeine-6-glucuronide (C6G) in the 
CEDIA buprenorphine assay was tested with spiked aliquots 
of the same negative urine sample pool from three healthy 
volunteers. The C6G analytical reference standard was sup-
plied by Lipomed AG (Arlesheim, Switzerland). The aliquots 
were spiked with different amounts of C6G giving C6G 
concentrations of 10,000 ng/mL, 20,000 ng/mL, 30,000 ng/
mL, and 40,000 ng/mL, before they were analyzed with the 
CEDIA buprenorphine assay.
Statistical analysis
In the patient samples, we defined true-positive results to be 
positive with both HPLC-MS/MS and CEDIA. True negative 
results were negative with both HPLC-MS/MS and CEDIA. 
False-positive samples were positive with CEDIA, but nega-
tive with HPLC-MS/MS, whereas false-negative samples 
were negative with CEDIA, but positive with HPLC-MS/
MS. From these results, we calculated sensitivity, specificity, 
positive predictive value (PPV), negative predictive value 
(NPV), and accuracy using Bayesian analysis.14 To find the 
most favorable CEDIA cutoff for buprenorphine in terms of 
highest specificity and sensitivity, we performed a receiver 
operating characteristic (ROC) analysis using Analyse-it 
(Analyse-it Software, Ltd, Leeds, UK). SPSS 20.0 (IBM 
Corporation, Armonk, NY, USA) was otherwise used to 
analyze the data. Pearson product moment correlation was 
used to analyze the relationship between C6G and CEDIA 
buprenorphine.







CEDIA buprenorphine assay yielded a positive result above 
the recommended cutoff concentration at 5 ng/mL in the 
first out of 15 urine samples collected 5 hours after a single 
administration of 60 mg of codeine phosphate and 800 mg 
of paracetamol (Table 1). The concentration of codeine, nor-
codeine, and C6G in that specific sample was 2,550 ng/mL, 
490 ng/mL, and 38,467 ng/mL, respectively, as determined 
by HPLC-MS/MS. The creatinine concentration was 
11.2 mg/dL. Response in the CEDIA buprenorphine assay 
was observed over 15 hours after administration, but it was 
below cutoff of 5 ng/mL in all other samples but the first. No 
other drugs-of-abuse were detected with HPLC-MS/MS. In 
all samples, creatinine concentrations were between 2.3 mg/
dL and 18.6 mg/dL, and pH was between 5.6 and 6.7.
The relationship between C6G concentrations and the sig-
nal in the CEDIA buprenorphine assay was linear (correlation 
coefficient =0.998) in negative urine samples spiked with 
C6G. A concentration of 40,000 ng/mL yielded a signal 
corresponding to 6.2 ng/mL in the CEDIA buprenorphine 
assay.
Performance study
Table 2 shows the distribution of the most frequently detected 
drugs in 2,272 patient urine samples. Almost half of the 
samples contained benzodiazepines, and clonazepam, and 
oxazepam were detected most frequently. Opioids other than 
methadone and buprenorphine were detected less frequently. 
Almost 5.4% of the samples were positive for morphine and 
2.5% for codeine. CEDIA rendered no false-negative results 
for buprenorphine, and the NPV was one in the 2,272 patient 
samples. Twenty-five urine samples (1.1%) had a positive 
buprenorphine result with the CEDIA assay in concentrations 
ranging from 5.00 ng/mL to 18.20 ng/mL, but no buprenor-
phine or metabolites detected by HPLC-MS/MS. Eighteen 
of these samples (72%) were positive for both codeine and 
morphine-3-glucuronide (M3G) in a concentration range of 
1,018–13,561 ng/mL, and 784–178,586 ng/mL, respectively 
(Table 3). Sixteen of these samples were also positive for 
morphine (17–37,665 ng/mL), and eleven for methadone 
(519–52,592 ng/mL). Five other samples were positive for 
methadone (9,446–41,866 ng/mL), either in addition to other 
drugs, such as oxazepam, delta-9-tetrahydrocannabinol, 
and zopiclone (n=3), or alone (n=2). One sample contained 
only oxazepam at a very low concentration, and in one other 
sample, no drugs or their metabolites were detected with 
our HPLC-MS/MS method. Taken together, the prevalence 
of false-positive urine samples for buprenorphine with 
the CEDIA assay was 1.1%, the sensitivity was 100%, the 
specificity was 98.0%, and the PPV was 0.957. In these 25 
samples, the lowest creatinine concentration was 3.9 mg/dL, 
the highest 50.4 mg/dL, and pH was between 5.4 and 7.6.
An increase in the cutoff concentration of the CEDIA 
buprenorphine assay would reduce the number of false-positive 
results but would render an increase in the number of 
Table 1 Results from urine samples (n=15) after ingestion of two tablets of a prescription drug containing 400 mg paracetamol +30 mg 
codeine phosphate by a healthy drug-naïve male volunteer
Timea CEDIA (ng/mL) HPLC-MS/MS (ng/mL)
Buprenorphine C6G Codeine Norcodeine Morphine M3G M6G
05.00 6.9 38,467 2,550 490 150 6,090 1,510
07.00 2.4 11,079 390 110 30 1,500 290
09.00 2.9 17,308 490 180 30 2,320 480
10.00 1.3 5,183 150 60 0 620 130
14.00 1.4 7,275 290 100 50 2,220 460
15.00 0.5 4,665 240 70 50 2,850 490
22.25 0.2 3,371 130 60 50 2,070 330
27.00 0 775 30 0 30 1,060 250
30.00 0.1 0 0 0 0 610 120
34.25 0 0 0 0 20 860 160
39.00 0 0 0 0 0 800 160
46.25 0 0 0 0 10 550 110
50.34 0.1 0 0 0 0 300 0
51.55 0.2 0 0 0 0 0 0
55.00 0 0 0 0 0 0 0
Note: aTime is given in hours and minutes after drug ingestion.
Abbreviations: ceDiA, cloned enzyme donor immunoassay; hPlc-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; c6g, codeine-6-
glucuronide; M3g, morphine-3-glucuronide; M6g, morphine-6-glucuronide.
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Table 2 Frequency and share of positive results for drugs-












Abbreviation: hPlc-MS/MS, high-performance liquid chromatography–tandem 
mass spectrometry.
Table 3 Results from ceDiA and hPlc-MS/MS in 25 urine samples with false-positive ceDiA buprenorphine
CEDIA (ng/mL) HPLC-MS/MS (ng/mL)
Buprenorphine C6G Codeine Norcodeine Morphine M3G M6G
18.20 91,294 13,561 4,166 200 3,138 646
18.10 17,165 1,018 788 26 784 185
16.70 0 0 0 0 0 0
15.00 41,938 5,149 1,121 57 2,538 600
11.20 9,415 2,335 1,070 37,665 139,823 48,915
10.60 11,602 3,832 970 27,621 178,586 68,758
9.60 11,174 1,766 143 36,253 120,903 46,146
8.60 0 0 0 0 0 0
7.60 4,279 1,467 51 29,390 125,056 48,454
7.30 4,336 1,168 94 23,826 127,825 42,778
7.10 37,801 2,096 1,067 29 2,123 415
7.10 12,172 2,604 1,104 14,096 148,129 46,608
6.90 29,861 3,682 705 314 9,137 1,661
6.90 0 0 0 0 0 0
6.80 24,820 1,736 297 19,118 117,673 40,609
6.80 0 0 0 0 0 0
6.30 2,948 1,078 86 12,441 97,368 20,997
6.30 0 0 0 0 0 0
6.20 30,479 5,868 962 86 1,154 231
6.00 0 0 0 0 0 0
5.90 8,464 1,527 611 9,245 105,213 31,656
5.80 27,626 1,676 1,273 57 3,092 461
5.40 19,020 1,078 514 17 3,461 600
5.20 6,419 1,197 254 8,389 108,444 23,073
5.00 0 0 0 0 0 0
Abbreviations: ceDiA, cloned enzyme donor immunoassay; hPlc-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; c6g, codeine-6-
glucuronide; M3g, morphine-3-glucuronide; M6g, morphine-6-glucuronide.
false-negative results instead. In a ROC curve for the buprenor-
phine assay, the area under the curve was approaching 1, 
which indicated a very good diagnostic accuracy. Figure 1 
shows PPV and NPV for CEDIA buprenorphine cutoff con-
centrations, ranging from 0 ng/mL to 49 ng/mL. The ROC 
analysis indicated that a cutoff concentration of 11.2 ng/mL 
would give the best accuracy, with four false-positive and two 
false-negative results, giving a PPV of 0.994 and a NPV of 
0.999. A cutoff concentration of 8.2 ng/mL would render no 
false-negative, but ten false-positive results.
Discussion
Principal findings
A single intake of a recommended therapeutic dose of 
60 mg codeine phosphate generated a false-positive CEDIA 
buprenorphine result. The concentration of codeine in 
this sample was 2,550 ng/mL. Codeine, morphine, and 
their respective metabolites were present in most of the 
false-positive patient urine samples. Raising the cutoff of the 
CEDIA buprenorphine assay from 5 ng/mL to 11.2 ng/mL 
decreased the risk of false-positive results, with only a modest 
increase in false-negative results giving both acceptable 
sensitivity and specificity.
Strengths and limitations
Cross-reactivity in the CEDIA buprenorphine assay has 
been described previously through experiments with spiked 
samples and in clinical case reports of false-positive urine 
 samples.5,9 In the present study, cross-reactivity was assessed 
in a drug-naïve person and in a large patient material 





associated with drug abuse. Importantly, our results dem-
onstrate that false-positive results in the CEDIA buprenor-
phine assay can occur after intake of a low dose of codeine 
by a person not associated with drug abuse. By using a 
known drug-naïve person, we minimized the risk of other 
possible cross-reactants that could cause a false-positive 
buprenorphine assay. We cannot completely rule out that 
paracetamol or its metabolites could cross-react with the 
CEDIA buprenorphine assay. Paracetamol is found on the 
negative list in the CEDIA buprenorphine assays cross-
reactivity guide, tested in a concentration of 500,000 ng/mL.9 
Considering that the chemical structure is quite different from 
buprenorphine, significant cross-reactivity with paracetamol 
is unlikely.
The patient samples in our study are representative 
for the target population of our drugs-of-abuse screen-
ing panel. This is illustrated by the high prevalence of 
positive results for several drugs-of-abuse. Our study 
results may demonstrate the magnitude of false-positive 
buprenorphine samples in a typical population for the use 
of drugs-of-abuse assays and as such represent a comple-
ment to cross-reactivity data supplied by the manufacturer. 
The presented data are generated from samples collected 
in a naturalistic setting with limited access to structured 
detailed information, including drug abuse pattern, treat-
ment modalities, or the presence of other diseases. Hence, 
differences in cross-reactivity between subgroups within this 
population could not be addressed. In particular, our study 
is limited by the fact that we do not have a complete drug 
subscription status of the patients. We therefore do not know 
whether substances other than the analyzed drugs-of-abuse 
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Figure 1 PPV and nPV with different cutoff concentrations of ceDiA for 
buprenorphine in patient urine samples (n=2,272).
Abbreviations: PPV, positive predictive value; nPV, negative predictive value; 
ceDiA, cloned enzyme donor immunoassay.
CEDIA  buprenorphine. For instance, in one case report, 
the antipsychotic amisulpride caused cross-reactivity with 
buprenorphine.15 In addition, our HPLC-MS/MS method 
only detects known analytes and has no screening option 
for other structurally related substances.
Possible cross-reactants
The manufacturer’s cross-reactivity guide serves to evaluate 
unexpected positive result in the CEDIA buprenorphine 
assay. According to this guide, the lowest concentration of 
codeine that yielded a false-positive result for buprenor-
phine was 34,000 ng/mL. This is in accordance with the 
data from spiked samples in other studies.5,11 In our study, 
the codeine concentrations associated with false-positive 
CEDIA buprenorphine were considerably lower, in the range 
of 1,000–13,500 ng/mL. This indicates that codeine alone did 
not cause the false-positive results. In the 18 samples with 
codeine, we also detected either codeine metabolites or other 
opioids and their metabolites. In our case study, the sample 
with a false-positive buprenorphine result had a concentration 
of 490 ng/mL and 38,467 ng/mL of norcodeine and C6G, 
respectively, in addition to codeine at a concentration of 
2,550 ng/mL. One of the patient samples in the performance 
study contained C6G in a concentration .50,000 ng/mL. 
Several samples contained C6G in concentrations between 
20,000 ng/mL and 50,000 ng/mL, concentrations that may 
have contributed to a false-positive buprenorphine result. 
These data are in accordance with data from Böttcher and 
Beck who demonstrated that C6G in a concentration of 
50,000 ng/mL gave a result around the CEDIA buprenorphine 
cutoff of 5 ng/mL.5 To confirm these findings, we spiked nega-
tive urine samples with C6G and found that a concentration 
of 40,000 ng/mL yielded a signal corresponding to 6.2 ng/
mL in the CEDIA buprenorphine assay.
Norcodeine concentrations were low (,4,200 ng/mL) in 
urine samples, which were false positive for buprenorphine. 
The manufacturer’s cross-reactivity guide did not evaluate 
norcodeine, but cross-reactivity with the CEDIA buprenor-
phine assay has been demonstrated when norcodeine con-
centrations were 100,000 ng/mL.5 Based on these data, the 
contribution of norcodeine to the overall cross-reactivity in 
our study population is probably negligible.
Some of the false-positive patient samples also contained 
morphine, M3G, morphine-6-glucuronide (M6G) in high 
enough concentrations to contribute to cross-reactivity. In a 
study where urine samples were spiked with different opioids, 
they showed cross-reactivity in the CEDIA buprenorphine 
assay for all the tested opioids.11 In a sample spiked with a 
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combination of dihydrocodeine and several metabolites of 
dihydrocodeine, in concentrations lower than what should 
give  significant cross-reactivity for each substance alone, 
CEDIA yielded a  positive buprenorphine result, indicating 
additive interference. We therefore suggest that a sum of 
structurally related compounds yielded a response above 
cutoff in the CEDIA buprenorphine assay in most of the 
false-positive samples in our study, although the concentra-
tion of each of them separately was lower than what is shown 
to give cross-reactivity in spiked samples.
In seven of the samples with false-positive CEDIA 
buprenorphine, no codeine, morphine, or their metabolites 
were detected with our HPLC-MS/MS method. Methadone was 
detected in five of these samples, oxazepam in two, and delta-
9-tetrahydrocannabinol and zopiclone in one. Methadone was 
the only detected substance in two of the five false-positive 
samples. Methadone concentrations .320,000 ng/mL have 
been shown to give significant cross-reactivity in the CEDIA 
buprenorphine assay.11 The methadone concentrations in these 
two samples and the other methadone-positive samples in our 
study material were considerably lower (all ,53,000 ng/mL). 
Oxazepam, delta-9-tetrahydrocannabinol, and zopiclone 
are structurally unrelated to opioids and are not known to 
cross-react with the CEDIA buprenorphine assay according 
to the manufacturer’s guide.9 Although we cannot rule out 
that these drugs could have contributed to a false-positive 
buprenorphine result, these seven samples may have con-
tained known cross-reactants that we did not analyze for, 
such as amisulpride and quetiapine.9
Urine codeine concentration
Codeine is reported to have interindividual pharmacoki-
netic variability,16 and it is therefore relevant to compare 
the urinary concentrations in the case study with results 
from previous published codeine elimination studies. In 
our case study, 5 hours after the administration of 60 mg 
of codeine phosphate, the CEDIA buprenorphine assay 
produced a response .5 ng/mL cutoff. The corresponding 
urine codeine concentration, as measured by HPLC-MS/MS, 
was 2,550 ng/mL. This codeine concentration is somewhat 
lower than the concentrations from a previous study in which 
the pattern of codeine and metabolites in urine was exam-
ined in five patients after the intake of 30 mg of codeine.17 
In that study, the urinary concentrations of codeine were 
ranging from 5,000 ng/mL to 20,000 ng/mL 12 hours after 
ingestion. In another study, four healthy volunteers were 
given 30 mg codeine phosphate. Codeine was detectable in 
urine from 1 hour to 24 hours, with a maximum excretion 
rate after 2 hours. The highest concentrations were between 
5,100 ng/mL and 13,300 ng/mL. Concentrations after 4 hours 
and 6 hours ranged from 500 ng/mL to 5,500 ng/mL.18 These 
data are in accordance with the results from our case study 
and strongly emphasize the clinical significance of cross-
reactivity in the CEDIA buprenorphine assay even after 
intake of therapeutic doses of codeine.
Codeine is mainly metabolized by glucuronidation to 
C6G. The amount of C6G may vary by ethnicity.16 Genetic 
variability in the activity of CYP2D6 does primarily affect 
the demethylation of codeine to morphine and norcodeine and 
to a lesser extent the glucuronidation to C6G.19 It is possible 
that genetic factors that contribute to variations in metabolite 
concentrations are of importance for the generation of 
false-positive CEDIA buprenorphine results after intake of 
therapeutic codeine doses. Future research may contribute 
to elucidate this question.
implications
If all urine samples positive for CEDIA buprenorphine were 
routinely analyzed also by a more specific method, such 
as HPLC-MS/MS, false-positive results would have been 
detected. Then, the recommended cutoff from the producer 
could be adequate, although the ROC analysis indicates that a 
higher cutoff would give a better accuracy in our population. 
Most buprenorphine-positive CEDIA samples, however, are 
not analyzed with HPLC-MS/MS in our laboratory, which is 
also common routine in several other  laboratories in Norway. 
With the CEDIA  buprenorphine assay, we have experienced 
that the clinicians may not question the assay results and 
may react also to false-positive samples with therapeutic 
means. These reactions include exclusion from drug abuse 
treatment institutions, more rigid treatment plans, and more 
frequent urine sample controls. In addition, false-positive 
samples could harm the doctor–patient relationship, giving 
both the doctor and the patient reason to lose confidence in 
each other. Therefore, we recommend increasing the cutoff 
for the CEDIA buprenorphine assay and propose 10 ng/mL 
for all practical reasons. Study results show that the higher 
cutoff does not completely remove the risk of false-positive 
samples. Clinicians should therefore be informed about the 
possible cross-reactivity and be encouraged to require a 
more specific analytical method in cases with unexpected 
positive CEDIA buprenorphine results. Still, a higher 
cutoff substantially diminishes the risk of false-positive 
samples caused both by codeine and its metabolites and 
other opioids, and thereby the risk of erroneous clinical 
interpretations.






Cross-reactivity in the CEDIA buprenorphine assay was seen 
even after intake of therapeutic doses of codeine phosphate. 
Metabolites of codeine and morphine may contribute to the 
cross-reactivity in urine samples from patients with drug 
abuse. The CEDIA buprenorphine cutoff concentration 
should be raised when the assay is used in a therapeutic set-
ting without confirmatory analyses. Furthermore, clinicians 
should be well informed about the risk of false-positive 
results with the CEDIA buprenorphine assay.
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Table S1 Analytical performance of hPlc-MS/MS for relevant analytes
Component Calibration rangea Limit of detectiona Imprecisionb (%)
6-Monoacetylmorphine 33–3,275 6.0 10.5
7-Aminoclonazepam 29–5,737 2.33 6.7
7-Aminoflunitrazepam 28–5,690 2.25 6.8
7-Aminonitrazepam 25–5,031 0.7 15.3
Alprazolam 31–6,178 0.9 5.1
Amphetamine 27–2,708 4.4 11.7
Benzoylecgonine 29–2,894 0.3 5.8
cocaine 6–608 0.2 12.0
codeine 30–2,997 6.9 16.3
codeine-6-glucuronide 95–9,511 5.0 15.3
Desmethyldiazepam 54–10,832 3.5 5.1
Diazepam 3–570 1.9 10.4
eDDP 28–2,775 0.8 29.1
ephedrine 33–3,320 5.5 13.6
ethylmorphine 31–3,137 7.7 13.4
hydrocodone 60–5,994 10.9 17.6
MDA 36–3,589 3.3 9.8
MDMA 39–3,873 1.0 10.7
Methadone 31–3,102 1.4 32.0
Methamphetamine 30–2,992 5.8 8.2
Morphine 29–2,855 9.0 17.1
Morphine-3-glucuronide 231–23,074 8.1 6.7
Morphine-6-glucuronide 139–13,851 15.0 8.5
N-desmethylzopiclone 38–7,513 2.6 7.5
norcodeine 29–2,880 8.8 20.2
Oxazepam 57–11,470 4.4 7.5
Oxycodone 63–6,313 7.2 10.1
Temazepam 60–12,069 2.6 4.8
Zopiclone-N-oxide 41–8,122 1.5 11.3
Notes: aconcentrations are given in ng/ml; btotal analytical imprecision is calculated based on performance at lowest calibrator plus 25%.
Abbreviations: hPlc-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; eDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; MDA, 
3,4-methylenedioxy-amphetamine; MDMA, 3,4-methylenedioxy-methamphetamine.
